A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
In this video Dr. John Allan describes the benefits of a recently opened clinical trial for men and women with CD20+ B-cell malignancies, including B-NHL and CLL.
If you’re interested in participating in this trial please call 212-746-2919 for more information. A full listing of B-cell malignancy trials at Weill Cornell Medicine can be found on the Joint Clinical Trials website.
Ibrutinib is a first-in-class oral Bruton’s tyrosine kinase inhibitor that has shown promise in treating a variety of relapsed and refractory B-cell malignancies. At the 2013 meeting of the American Society of Clinical Oncology in Chicago, Dr. Anas Younes of the MD Anderson Cancer Center presented results from a recent phase 1b trial combining ibrutinib with standard doses of R-CHOP in patients with previously untreated CD20 positive NHL (NCT01569750).
A total of seventeen patients were enrolled, including those with subtypes of diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. The recommended phase 2 dose of ibrutinib was established at 560 mg daily in combination with standard doses of R-CHOP given every 21 days. The overall response rate of treatment was 100% with 7 complete and 3 partial responses in 10 evaluable patients. The most common adverse events were neutropenia (77%), thrombocytopenia (65%), vomiting (59%), anemia (53%), nausea (47%), fatigue (35%), headaches (29%), constipation (24%), diarrhea (24%), and dizziness (24%).
The study concluded that this novel combination of Ibrutinib and R-CHOP has an acceptable and expected safety profile. An expansion cohort 560 mg ibrutinib is being opened to further explore the safety and efficacy of IR-CHOP in patients with newly diagnosed diffuse large B-cell lymphomas.
For a full listing of all current clinical trials underway in the Lymphoma Program, please click here.
New Developments in Lymphoma 